Sana Biotechnology Inc (SANA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $563.31M
Last updated: Nov 17, 2026 at 4:42 PM ET
Sana Biotechnology Inc (SANA) Statistics
Sana Biotechnology (SANA) has a market cap of $563.31M and an enterprise value of $603.38M. Revenue fell 100.00% over the last 12 months from the 12 months before. Its share count is up 17.85% from a year earlier.
Total Valuation
Enterprise value is 7.11% above the market cap, as debt exceeds cash.
| Market Cap | $563.31M |
|---|---|
| Enterprise Value | $603.38M |
| Latest price (Nov 17, 2026) | $1.88 |
Key Dates
The next earnings report is expected on Mar 1, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 1, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 52.88% over 52 weeks and trades 29.06% below its 50-day average.
| Beta (1Y) | 2.17 |
|---|---|
| 52-Week Change | -52.88% |
| 1-Month Change | -18.26% |
| 3-Month Change | -54.15% |
| 6-Month Change | -38.56% |
| 5-Year Change | -87.61% |
| Total Return (1Y) | -52.88% |
| Total Return (3Y CAGR) | -23.50% |
| Total Return (5Y CAGR) | -38.27% |
| Return vs SPY (1Y) | -58.30% |
| Max Drawdown (1Y) | -63.71% |
| Max Drawdown (3Y) | -88.11% |
| Sharpe Ratio (1Y) | -0.85 |
| Correlation with SPY (1Y) | 0.40 |
| 50-Day Average | $2.65 |
| 200-Day Average | $3.25 |
| 52-Week Range | $1.86 to $5.49 |
| RSI (14 Days) | 29.8 |
| Average Volume (20 Days) | 2.71M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.77x current liabilities, and total debt is 0.45x shareholder equity.
| Current Ratio | 1.77x |
|---|---|
| Quick Ratio | 1.77x |
| Debt / Equity | 0.45x |
Returns and Efficiency
Return on invested capital is -46.80% over the last 12 months, against a 5-year average of -74.62%.
| Return on Equity (ROE) | -82.76% |
|---|---|
| Return on Assets (ROA) | -39.69% |
| Return on Invested Capital (ROIC) | -46.80% |
| ROE (5Y Average) | -91.92% |
| ROA (5Y Average) | -45.24% |
| ROIC (5Y Average) | -74.62% |
Scores
SANA has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$3.05M |
| Operating Income | -$156.73M |
| Pretax Income | -$151.57M |
| Net Income | -$149.27M |
| EBITDA | -$144.29M |
| Reported EPS (TTM) | -$0.57 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 47.95% of the $376.13M in total assets.
| Cash and Equivalents | $41.10M |
|---|---|
| Total Debt | $81.17M |
| Net Debt | $40.07M |
| Net Debt Per Share | $0.13 |
| Working Capital | $57.43M |
| Shareholder Equity | $180.36M |
| Book Value Per Share | $0.59 |
| Tangible Book Value | -$19.46M |
| Total Assets | $376.13M |
| Total Liabilities | $195.76M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $3.57M of capital spending, operating cash flow left -$145.13M of free cash flow.
| Operating Cash Flow | -$141.56M |
|---|---|
| Capital Expenditures | $3.57M |
| Free Cash Flow | -$145.13M |
| FCF Per Share | -$0.48 |
| Depreciation and Amortization | $10.65M |
Trailing 12 months through Sep 30, 2026.
Dividends and Yields
SANA does not pay a dividend. Its free cash flow yield is -25.15%.
| FCF Yield | -25.15% |
|---|---|
| Buyback Yield | -19.30% |
| Shareholder Yield | -19.30% |
Peer Position
Against 3 similar companies, SANA has the 3rd highest ROIC.
ROICPeer median -38.29%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -97.79%
| ROIC | -46.80% vs -38.29% median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -100.00% vs -97.79% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About SANA
What is SANA's market cap?
Sana Biotechnology has a market cap of $563.31M. Its enterprise value, which adds debt and subtracts cash, is $603.38M.
How many shares of SANA are outstanding?
Sana Biotechnology has 307.00M shares outstanding. The count is up 17.85% from a year earlier.
Does SANA pay a dividend?
No. Sana Biotechnology does not pay a dividend.
How much debt does SANA have?
Sana Biotechnology has $81.17M of total debt and $41.10M of cash and equivalents, a net debt position of $40.07M.
SANA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors